Cracking The Code: Understanding Analyst Reviews For CollPlant Biotechnologies
Portfolio Pulse from Benzinga Insights
CollPlant Biotechnologies (NASDAQ:CLGN) has been evaluated by 4 analysts over the past three months, all giving bullish ratings. The average 12-month price target is $12.5, up from $12. Analysts from HC Wainwright & Co. and EF Hutton maintain 'Buy' ratings with price targets of $11 and $14, respectively. Despite a strong market presence, CollPlant faces revenue challenges with a significant decline in growth, but maintains a strong net margin and ROE.
August 21, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CollPlant Biotechnologies has received bullish ratings from 4 analysts, with a 12-month price target average of $12.5, indicating positive sentiment. However, the company faces significant revenue challenges with a decline of -77.37% over the past three months.
The bullish ratings and increased price target suggest positive short-term sentiment, likely leading to a stock price increase. However, the significant revenue decline poses a risk, which may temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100